7WU-33936-38830
3 vaccinations
2 coded responses
25 check-ins
2 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 61-65
- ZIP prefix
- 704 / LA
- Registered
- 2020-12-30
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-29
Dose 1 — Pfizer-BioNTech
-
2020-12-30
Registered in v-safe
- 2020-12-30
- 2020-12-31
- 2021-01-01
- 2021-01-02
- 2021-01-03
- 2021-01-04
- 2021-01-05
- 2021-01-12
-
2021-01-19
Dose 2 — Pfizer-BioNTech
- 2021-01-19
- 2021-01-21
- 2021-01-22
- 2021-01-23
- 2021-01-24
- 2021-01-25
- 2021-01-26
- 2021-02-02
- 2021-02-09
- 2021-02-16
- 2021-02-23
- 2021-03-02
-
2021-04-20
Survey response — 3 months, dose 2MedDRA: Lymphadenopathy — Feeling: GoodFree text: Breast MRI showed mild enlargement of lymph nodes in left Axilla and axillary tail which may be residual of vaccination received on same arm. Radiologist is recommending ultrasound of all axillary lymph nodes.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-07-20
- 2022-01-19
-
2022-07-30
Dose 3 — Pfizer-BioNTech
-
2022-10-29
Survey response — 3 months, dose 3MedDRA: Condition aggravated, Pre-existing disease — Feeling: GoodFree text: Myeloperoxidase blood level extremely elevated- tested 10 after receiving Covid booster. History-normal myeloperoxidase past 2 years. No cardiac symptoms, chest pain or shortness of breath. Myeloperoxidase tested as part of employer wellness program.MedDRA releases: 2024-11 · check-in free text available
- 2023-01-28
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-29 | Pfizer-BioNTech | |
| 2 | 2021-01-19 | Pfizer-BioNTech | |
| 3 | 2022-07-30 | Pfizer-BioNTech | No |
Free text
Release 7 — 3 months, dose 2
Symptoms: Breast MRI showed mild enlargement of lymph nodes in left Axilla and axillary tail which may be residual of vaccination received on same arm. Radiologist is recommending ultrasound of all axillary lymph nodes.
Release 12 — 3 months, dose 3
Symptoms: Myeloperoxidase blood level extremely elevated- tested 10 after receiving Covid booster. History-normal myeloperoxidase past 2 years. No cardiac symptoms, chest pain or shortness of breath. Myeloperoxidase tested as part of employer wellness program. cut off by CDC
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Condition aggravated | · | · | ✓ |
| SD | Lymphadenopathy | ✓ | ✓ | ✓ |
| SD | Pre-existing disease | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release